Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Not Applicable

Completed

• Conditions: Repeated Implantation Failure
• Interventions: Drug: atosiban

• Registration Number: NCT01493440
• Lead Sponsor: An Sinh Hospital

Brief Summary

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Detailed Description

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Study Timeline

• Study Start: 2011-03
• Primary Completion: 2011-08
• Study Completion: 2011-09
• Status Verified: 2011-12
• Study First Submitted: 2011-12-14
• Study First Submitted QC: 2011-12-15
• Study First Posted: 2011-12-16
• Last Update Submitted: 2011-12-16
• Last Update Posted: 2011-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 71

Inclusion Criteria

• had repeated implantation failure
• have at least 1 good quality embryo for transfer

Exclusion Criteria

• uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Atosiban	atosiban	-

Primary Outcome Measures

Name	Time	Method
Clinical pregnancy	5 weeks after intervention

Trial Locations

Locations (1)

IVFAS, An Sinh Hospital; 🇻🇳 Ho Chi Minh City, Ho Chi Minh, Vietnam